Loading...
NPI 1205844750 · Las Vegas, NV · Hematology & Oncology Physician
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Clark Jean is a hematology & oncology physician provider located in Las Vegas, Nevada. This profile covers 93 Medicare and 7 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Individual |
| Organization | Clark Jean |
| Address | 7445 Peak Dr |
| City | Las Vegas |
| State | NV |
| ZIP | 89128 |
| Taxonomy | Hematology & Oncology Physician |
| NPI Enumerated | August 3, 2006 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $4.2M |
| Medicaid | $21.8K |
This provider’s revenue is overwhelmingly Medicare-driven: Total Medicare revenue is $4.2M versus Total Medicaid revenue of $21.8K, indicating Medicare accounts for the vast majority of billed dollars and the provider functions effectively as a Medicare-focused practice. Medicaid activity is present but nominal in scale compared with Medicare, suggesting payer-mix risk is concentrated on Medicare reimbursement patterns.
Medicare revenue is highly concentrated in a small set of high-cost oncology items — the precomputed top 3 Medicare codes account for 60.3% of Medicare revenue. Specifically, J9271 generated $1M (26.4% of Medicare revenue) and J9144 generated $991.4K (25.2% of Medicare revenue), with imaging via 78815 contributing $344.3K (8.7% of Medicare revenue), signaling the business is centered on high-cost immunotherapy infusions supplemented by PET/CT imaging.
The code mix and top-billing items indicate an infusion- and imaging-centric hematology/oncology operation: large volumes of antibody immunotherapies (J9271, J9144, J9299) and supportive oncology drugs (e.g., J0897, J1930, J0881) appear alongside PET/CT imaging (78815/78816) and chemotherapy administration codes (96413), consistent with an outpatient oncology infusion clinic that integrates diagnostic imaging and systemic therapy. These patterns are typical for a hematology & oncology physician practice focused on active cancer care and supportive therapies.
On competitive standing, the provider shows differentiated national volume for specific drugs: J9144 ranks #23 of 615 providers nationally (96th percentile) and is described as "notably above typical national volume," indicating this provider is a relatively high-volume national billing source for daratumumab. J9041 also ranks highly (#9 of 357, 98th percentile; "notably above typical national volume") and 96413 ranks #322 of 7514 (96th percentile; "notably above typical national volume"), whereas J9271 ranks #243 of 1841 (87th percentile; characterized as typical/unremarkable).
There are statistical outliers in evaluation & management coding: 99213 for Medicare is listed as an "extreme outlier" (rank #1861 of 457151 providers, 100th percentile) and 99204 is also an "extreme outlier" (rank #3341 of 227068 providers, 99th percentile). Although these E/M codes represent smaller shares of Medicare revenue (99213 at $102.1K, 2.6% and 99204 at $28.4K, 0.7%), the exceptionally high national rank suggests the provider bills unusually large volumes of office visits relative to peers, which could reflect a high outpatient visit throughput or different coding practices.
Medicaid billing is tightly concentrated: the precomputed top 3 Medicaid codes account for 84.7% of Medicaid revenue, with 99213 alone representing $14.8K (68.2% of Medicaid revenue) from 235 claims. The Medicaid mix is dominated by office visits and a small volume of chemotherapy administration (96413 $2K, 9.0% of Medicaid revenue), indicating Medicaid-facing activity is primarily ambulatory E/M encounters rather than high-dollar drug or imaging services.
Operationally, the practice handles a mix of high-cost biologic infusions and routine supportive care: Medicare line items include large claim counts for drug codes such as J9271 (24.2K claims), J9144 (27.5K claims), and J0881 (44.5K claims) alongside infusion/chemotherapy administration codes (96413 652 claims, 96401 392 claims). This combination suggests established infusion throughput and inventory/administration capabilities needed to support frequent monoclonal antibody and supportive agent delivery in an outpatient setting.
The provider has long-tenured enrollment: NPI enumerated 2006-08-03 (~20 years ago), which supports interpretation of the coding and volume profile as reflecting an established oncology practice rather than a new entrant. Given the concentration of high-revenue Medicare drug codes and high national ranks for several therapy codes, analysts should view this entity as an experienced outpatient oncology biller with concentrated Medicare exposure and minimal Medicaid revenue at present.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
93 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | 24,200 | $40 | $1M |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase‑fihj | 27,540 | $40 | $991.4K |
| 78815 | PET and CT scans are both standard imaging tools that allow doctors to evaluate the location and metabolic actions of tumors or cancer inside the body before beginning an active treatment regimen.… | 270 | $1,280 | $344.3K |
| J9299 | Injection, nivolumab, 1 mg | 13,760 | $20 | $316.5K |
| J1930 | Injection, lanreotide, 1 mg | 5,520 | $40 | $242.9K |
| J0897 | Injection, denosumab, 1 mg | 9,660 | $20 | $173.9K |
| J1568 | Injection, immune globulin, (octagam), intravenous, non-lyophilized (e.g., liquid), 500 mg | 3,220 | $30 | $106.3K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,570 | $70 | $102K |
| J0881 | Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 44,520 | $1 | $89K |
| A9595 | Piflufolastat f-18, diagnostic, 1 millicurie | 180 | $490 | $87.8K |
Showing 1–10 of 93
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 93 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
93 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| J9271 | 3 | 40 | 13,000 | $40 | $625.8K |
| J9144 | 1 | 10 | 9,180 | $40 | $445.4K |
| J9299 | 6 | 10 | 14,400 | $20 | $362K |
| J1930 | 2 | 10 | 5,820 | $40 | $255K |
| J1568 | 11 | 10 | 4,470 | $30 | $164.2K |
| A9595 | 2 | 10 | 150 | $490 | $109.6K |
| J0897 | 9 | 70 | 3,630 | $20 | $94.6K |
| 78815 | 3 | 60 | 60 | $930 | $80.4K |
| J0881 | 4 | 30 | 17,400 | $1 | $49.5K |
| Q5122 | 3 | 10 | 350 | $90 | $37.7K |
Showing 1–10 of 93
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
7 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 240 | $60 | $14.8K |
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 20 | $120 | $2K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 10 | $140 | $1.6K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 40 | $40 | $1.5K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 150 | $10 | $1K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 80 | $10 | $750 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 20 | $1 | $30 |
How this provider's Medicaid billing volume and revenue compare to other Nevada providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Nevada median
7 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| 96413 | Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These… | 18 | 20 | 240 | $90 | $189.3K |
| 96375 | Following the administration of a drug or other substance via intravenous, or IV, push, the provider sequentially infuses a different medication or medications, also via IV push. He administers the… | 64 | 70 | 2,110 | $10 | $114.5K |
| 99213 | The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a low level of medical decision making, and/or the… | 1,421 | 2,480 | 330 | $50 | $107.6K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 103 | 130 | 1,600 | $1 | $74.9K |
| 99204 | The provider sees a new patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the provider… | 746 | 780 | 90 | $100 | $46.6K |
| 85025 | A complete blood count (better known as a CBC) is a blood test request by a doctor that provides detailed information about various types of cells in a patient's blood. Usually a pathologist or a… | 108 | 160 | 1,190 | $1 | $39.8K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | 138 | 150 | 180 | $1 | $1.4K |
Other providers in the same ZIP code as Clark Jean, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.